Related Experiment Video
Updated: Oct 14, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
Hilary Dietz1, Sophia C Weinmann2, April K Salama1
1Division of Medical Oncology, Duke University, Durham, NC, USA.
Abstract:
The development of immune checkpoint inhibitors (ICI) has dramatically changed the clinical management of metastatic melanoma and other solid tumors. Despite exclusion from initial clinical trials, there is a growing body of retrospective data that suggest ICI can be used in patients with underlying autoimmune disease (AID) with a tolerable level of anticipated immune-related adverse events (irAEs) and a rate of severe irAEs comparable to that of patients without underlying AID. Coordination with other subspecialists and careful monitoring for irAEs is critical in safely managing these patients. Studies exploring novel approaches examining the use of targeted immunosuppressants in the prevention and management of irAEs, as well as multiple studies currently underway are aimed at establishing safe clinical practices when using ICI in patients with underlying AID.
Related Concept Videos
Tumor Immunotherapy
The Intrinsic Apoptotic Pathway
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Inhibition of Cdk Activity
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

